Condition: Clear Cell Renal Cell Carcinoma · Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON Clinicaltrial.gov ID: NCT03849118)
This description comes directly from the study's public registry record.
Lily Nahidi · +61 3909 33871 · lily.nahidi@telixpharma.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | Recruiting |
| Zhejiang Provincial People's Hospital | Hangzhou, China | Not Yet Recruiting |
| Union Hospital Tongji Medical College Huazhong University Of Science And Technology | Hubei, China | Not Yet Recruiting |
| Zhongshan Hospital, Fudan University | Shanghai, China | Not Yet Recruiting |
| The First Affiliated Hospital of Soochow University | Suzhou, China | Not Yet Recruiting |
| Tianjin Cancer Hospital Airport Hospital | Tianjin, China | Not Yet Recruiting |
| Affiliated Hospital Of Jiangnan University | Wuxi, China | Not Yet Recruiting |
| Zhejiang Cancer Hospital | Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06750419